Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06355440
Other study ID # 2312288-16
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 18, 2024
Est. completion date June 30, 2024

Study information

Verified date April 2024
Source Fudan University
Contact Xiaoyi Yuan, Master
Phone (+86) 18918305439
Email 22211170009@m.fudan.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this pilot study is to access the feasibility and impact of a financial navigation program on improving financial toxicity among patients with breast cancer in China. The main questions it aims to answer are: - Is the intervention feasible and acceptable among participants? - Does the intervention enhance participants' cost-related health literacy? - Does the intervention reduce participants' financial toxicity? Researchers will compare the financial navigation program with usual oncology care to preliminarily evaluate its effectiveness. Participants will receive comprehensive information support, including: - Strategies on patient-physician costs discussion - Skills for inquiring and tracking treatment-related costs - Basic knowledge about health insurance - Guidance on accessing and applying for financial assistance - Suggestions for returning to normal life and work - Strategies for holding a financial-related family meeting


Recruitment information / eligibility

Status Recruiting
Enrollment 24
Est. completion date June 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - (1) Newly diagnosed with breast cancer and undergoing surgery during this admission; - (2) Female, age 18 years or older; - (3) Receiving or expected to receive one or more of the following therapies: chemotherapy, radiotherapy, endocrine therapy, targeted therapy, and immunotherapy; - (4) Eastern Cooperative Oncology Group Performance Status 0-2; - (5) Provided informed consent to participate in this study. Exclusion Criteria: - (1) Diagnosed with ductal carcinoma in situ (DCIS) - (2) Presence of any serious psychiatric disorders; - (3) Cognitive impairments; - (4) Difficulty in reading, writing, or communicating in Chinese.

Study Design


Intervention

Behavioral:
Financial Navigation
One-on-one information support with material booklets during hospitalization. Weekly financial navigation information will be sent via WeChat after discharge for 1 month. The financial navigation encompasses comprehensive information support: Strategies on patient-physician costs discussion Skills for inquiring and tracking treatment-related costs Basic knowledge about health insurance Guidance on accessing and applying for financial assistance Suggestions for returning to normal life and work Strategies for holding a financial-related family meeting
Other:
Usual Care
Participants will receive usual oncology care during hospitalization and regular follow-up after discharge. Participants have the freedom to utilize any financial resources, but financial navigators do not offer comprehensive information support.

Locations

Country Name City State
China Fudan University Shanghai Cancer Center Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Eligibility rate The eligibility rate will be calculated as the proportion of participants who meet the eligibility criteria among the total number of participants who will be assessed for eligibility. Reasons for participants' ineligibility will be recorded. Approximately 1 month
Primary Consent rate The consent rate will be calculated as the proportion of eligible participants who consent to participate among those who will be approached and eligible for participation. Reasons for participants' refusal to participate will be recorded. Approximately 1 month
Primary Retention rate The retention rate will be calculated as the percentage of participants who withdraw from or drop out of the study after enrolment. Reasons for participants' withdrawal or dropout will be recorded. Through study completion, an average of 3 month
Primary Adherence rate The adherence rate will be calculated as the proportion of participants completing the entire program. Reasons for participants' nonadherence to the intervention will be recorded. Through study completion, an average of 3 month
Primary Patient-reported satisfaction Participants' satisfaction will be measured with homemade 5 item questionnaire, with higher scores indicating higher satisfaction. 1 month after discharge in Financial Navigation Arm
Primary Qualitative assessment of the intervention Participants' experiences will be captured through one-on-one, semi-structured qualitative interviews. 1 month after discharge in Financial Navigation Arm
Secondary Cost-related health literacy The cost-related health literacy will be measured with homemade 10-item questionnaire, with higher scores indicating higher cost-related health literacy. Baseline, 1 month after discharge
Secondary Financial toxicity Financial toxicity will be measured with the Comprehensive Score for Financial Toxicity-Functional Assessment of Chronic Illness Therapy Version 2 (COST-FACIT-V2); lower scores (range, 0-44) indicating greater financial toxicity. Baseline, 1 month after discharge
Secondary Material domain of financial toxicity Material domain of financial toxicity will be measured with 2 items adapted from the Medical Expenditure Panel Survey (MEPS). Baseline, 1 month after discharge
Secondary Behavioral domain of financial toxicity Behavioral domain of financial toxicity will be measured by employment changes and cost-related nonadherence with 6 items adapted from MEPS and previous literature. Baseline, 1 month after discharge
See also
  Status Clinical Trial Phase
Completed NCT03980626 - Study on Physical Activity's Relationship With Cancer and Cognition N/A
Completed NCT04329819 - Satisfaction and QUality of Life After Breast REconstruction
Recruiting NCT03323346 - Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer Phase 2
Recruiting NCT03900884 - Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer Phase 1
Completed NCT05042999 - The Use of Virtual Reality During Breast Ultrasound-Guided Biopsy Procedures N/A
Not yet recruiting NCT03662633 - Diagnosis Value of SEMA4C in Breast Cancer
Recruiting NCT05075512 - The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer Phase 2
Recruiting NCT04456855 - Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
Not yet recruiting NCT03629509 - BEFORE Decision Aid Implementation Study N/A
Completed NCT04811378 - HaemoCerTM Application in Breast Cancer Surgery N/A
Completed NCT03198442 - Breast PET Feasibility N/A
Not yet recruiting NCT05577442 - Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer Phase 2
Enrolling by invitation NCT04047823 - Temperature and Injury in Radiotherapy Radiation Skin Injury
Recruiting NCT05452213 - Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients Phase 4
Recruiting NCT05027321 - Efficacy of Preparation in Self-Hypnosis by Anchoring Versus Conversational Hypnosis, Used Alone or Combined, in Patients Undergoing Breast Macrobiopsies N/A
Active, not recruiting NCT04812652 - Digitally Distributed Yoga for Women Treated for Breast Cancer N/A
Active, not recruiting NCT03425838 - Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer Phase 3
Completed NCT05473026 - Grateful Strides Toward Physical Activity and Well-Being for Black Breast Cancer Survivors N/A
Completed NCT04509063 - Investigating Public Enthusiasm for Mammography Screening in Denmark N/A
Recruiting NCT05711030 - Thoracic Paravertebral Block Anesthesia for Breast Cancer Surgery N/A